Erteberel (LY500307) is primarily investigated for its potential therapeutic applications in neurological and psychiatric disorders. It functions as a selective estrogen receptor beta (ERβ) agonist, which makes it a promising candidate for treating conditions like schizophrenia, Parkinson’s disease, and depression. By modulating ERβ activity, it may help reduce neuroinflammation, promote neurogenesis, and enhance cognitive function. Additionally, it is being studied for its role in mitigating the effects of neurodegenerative diseases by protecting neurons from oxidative stress and apoptosis. Its potential to improve mood and memory also positions it as a valuable compound in addressing mental health challenges.